Novartis India Ltd

Bal Pharma Ltd, Anmol India Ltd, Medi Caps Ltd and Goa Carbon Ltd are among the other gainers in the BSE's 'B' group today, 09 September 2026.Novartis India Ltd surged 20.00% to Rs 2188 at 12:03 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 53989 shares were traded on the counter so far as against the average daily volumes of 10661 shares in the past one month. Bal Pharma Ltd spiked 20.00% to Rs 114.02. The stock was the second biggest gainer in 'B' group. On the BSE, 56599 shares were traded on the counter so far as against the average daily volumes of 2500 shares in the past one month. Anmol India Ltd soared 17.95% to Rs 13.34. The stock was the third biggest gainer in 'B' group. On the BSE, 1.97 lakh shares were traded on the counter so far as against the average daily volumes of 9117 shares in the past one month. Medi Caps Ltd gained 17.41% to Rs 31.7. The stock was the fourth biggest gainer in 'B' group. On the BSE, 26182 shares were traded on the counter so far as against the average daily volumes of 1661 shares in the past one month. Goa Carbon Ltd rose 16.74% to Rs 452.55. The stock was the fifth biggest gainer in 'B' group. On the BSE, 1.48 lakh shares were traded on the counter so far as against the average daily volumes of 850 shares in the past one month.

Novartis India Limited announced that its Board of Directors approved the adoption of a new Memorandum of Association to align with the Companies Act, 2013, and a proposal to change the company’s name, both subject to shareholder approval at the upcoming Annual General Meeting. The decisions were made at a board meeting held on Monday, August 17, 2026, and also included an amendment to the Notice of the 78th Annual General Meeting previously approved on August 7, 2026.

Novartis India Limited informed the BSE Limited that its board approved the termination of a distribution and promotion agreement with Dr. Reddy’s Laboratories Limited, dated February 11, 2022, with an effective termination date of September 30, 2026, to re-acquire exclusivity and secure market access for certain products.

Novartis India Limited (NIL), a BSE-listed Indian pharmaceutical company, announced that ChrysCapital has acquired a controlling 70.68% stake in the organization, marking its first majority-controlled investment in the Indian pharmaceutical sector. The transaction will see NIL adopt a new name and corporate identity, and Dr. Vikas Gupta has been appointed as Managing Director and Chief Executive Officer, with Ramesh Ramadurai assuming the role of Chairperson of the NIL board.

Net profit of Novartis India rose 16.62% to Rs 32.21 crore in the quarter ended June 2026 as against Rs 27.62 crore during the previous quarter ended June 2025. Sales rose 18.57% to Rs 103.81 crore in the quarter ended June 2026 as against Rs 87.55 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales103.8187.55 19 OPM %33.6331.11 - PBDT43.5937.75 15 PBT43.1737.22 16 NP32.2127.62 17 Powered by Capital Market - Live

Novartis India will hold a meeting of the Board of Directors of the Company on 23 July 2026.

Net profit of Novartis India declined 13.82% to Rs 25.25 crore in the quarter ended March 2026 as against Rs 29.30 crore during the previous quarter ended March 2025. Sales rose 7.95% to Rs 90.55 crore in the quarter ended March 2026 as against Rs 83.88 crore during the previous quarter ended March 2025. For the full year,net profit declined 7.65% to Rs 93.18 crore in the year ended March 2026 as against Rs 100.90 crore during the previous year ended March 2025. Sales declined 0.54% to Rs 354.33 crore in the year ended March 2026 as against Rs 356.27 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales90.5583.88 8 354.33356.27 -1 OPM %22.7728.51 -26.5625.66 - PBDT30.5634.42 -11 131.61132.61 -1 PBT30.1433.89 -11 129.66130.42 -1 NP25.2529.30 -14 93.18100.90 -8 Powered by Capital Market - Live

Novartis India will hold a meeting of the Board of Directors of the Company on 12 May 2026.

Novartis India announced that Sandra Martyres (DIN: 00798406), Independent Director, shall be completing her second and final term as an Independent Director of the Company on 18 April 2026. Accordingly, she ceases to be the Director of the Company w.e.f. close of business hours of 18 April 2026.Powered by Capital Market - Live

The board of Novartis India at its meeting held on 27 March 2026 has approved the appointment of Gowree Gokhale (DIN: 09351661) as an Additional Director (designated as Non-Executive and Independent Director) on the Board of the Company for a period of 5 (five) consecutive years with effect from 01 April 2026 up to 31 March 2031, subject to approval of the Members of the Company. Powered by Capital Market - Live